Physician profile
Stephen G Vance
NPI 1154341345
$5,345.65
in general payments reported to CMS, 2019-2025
51 companies · $936 in 2025
The $936 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $108 · 2021: $1,173 · 2022: $947 · 2023: $713 · 2024: $473 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,125.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $561.91 | 2019-2024 | Otezla, Repatha, Prolia |
| Biotronik INC. | $331.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.23 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $305.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $282.76 | 2021-2024 | Vraylar |
| Abbott Laboratories | $202.12 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $193.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $184.33 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $153.25 | 2019-2022 | |
| Exact Sciences Corporation | $143.79 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $137.13 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $115.72 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $107.55 | 2019-2023 | Farxiga |
| Sunovion Pharmaceuticals INC. | $94.85 | 2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.